Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers
NCT ID: NCT04666012
Last Updated: 2023-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
150 participants
INTERVENTIONAL
2020-12-29
2023-03-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
NCT05047692
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
NCT05576623
Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Adults
NCT04911790
GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19)
NCT04673149
A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19
NCT04869592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: low dose
Subject will receive single dose of AdCLD-CoV19(2.5x10\^10VP) as intramuscular injection.
AdCLD-CoV19
Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Group 2: middle dose
Subject will receive single dose of AdCLD-CoV19(5.0x10\^10VP) as intramuscular injection.
AdCLD-CoV19
Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Group 3: high dose
Subject will receive single dose of AdCLD-CoV19(1.0x10\^11VP) as intramuscular injection.
AdCLD-CoV19
Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Group 4: selected dose
Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
AdCLD-CoV19
Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Group 5: selected dose
Subject will receive single dose of AdCLD-CoV19 as intramuscular injection.
AdCLD-CoV19
Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AdCLD-CoV19
Replication-defective human adenovirus type 5/35 vector based vaccine expressing S protein of SARS-CoV-2.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The BMI index is 18.5 kg/m2 to 30.0 kg/m2.
3. Weigh 40kg to 100kg (Part A only)
4. Able and willing to medically effective contraception during the whole study period.
5. Agreement to refrain from blood donation during the whole study period.
Exclusion Criteria
2. Determined to be a close-contact of SARS-CoV-2 confirmed case or classified to symptomatic patient of COVID-19 prior to vaccination.
3. Clinically significant abnormal ranges of laboratory measurement, ECG, Chest X-ray at screening visit.
4. Positive in HIV, HBV, HCV test at screening visit.
5. Acute fever(≥ 38℃) or suspected infectious disease, symptoms of infectious disease(cough, difficulty breathing, chills, muscle aches, headache, sore throat, loss of smell, or loss of taste, etc.) within 3 days prior to vaccination.
6. Chronic respiratory disease: Asthma, chronic obstructive pulmonary disease, active tuberculosis, latent tuberculosis under treatment.
7. Clinically significant active or any history of disease: Hepatobiliary system, kidney, central or peripheral nervous system (epilepsy, seizure, etc.), endocrine system (uncontrolled diabetes, hyperlipidemia, etc.), cardiovascular system (congestive heart failure, coronary artery disease, myocardial infarction, control Hypertension, etc.), blood tumor, urinary system, mental, musculoskeletal system, immune system (rheumatoid arthritis, systemic lupus erythematosus).
8. Immunosuppressive disease including immunodeficiency disease.
9. Scheduled to undergo any surgery during the whole study period.
10. Healthcare worker who provide medical care to SARS-CoV-2 cases or occupationally in high risk for SARS-CoV-2 exposure during the whole study period.
11. Prisoners or subjects who are compulsorily detained. (involuntary incarceration)
12. History of SARS or MERS.
13. Allergic reaction or hypersensitivity to any ingredient of AdCLD-CoV19.
14. Having hemophilia at risk of causing serious bleeding when injected intramuscularly or receiving anticoagulants.
15. Any history of malignant disease within the past 5 years.
16. History of hypersensitivity to inoculate vaccine such as Guillain-Barre syndrome.
17. History of serious adverse reaction or allergic reaction to inoculate vaccine.
18. Urticaria past 5 years prior to vaccination.
19. History of hereditary angioneurotic edema or acquired angioneurotic edema.
20. History of solid organ or bone marrow transplantation.
21. Suspected or a history of drug or alcohol abuse past 12 month before vaccination.
22. Receipt of vaccine of SARS-CoV, MERS-CoV, SARS-CoV-2.
23. Receipt of adenovirus vector based vaccine.
24. Chronic use of immunosuppressant or immune modifying drug within 6 months prior to vaccination. (use of inhaled, topical, nasal, and ophthalmic corticosteroids are allowed)
25. Having relied on antipsychotic drugs and narcotic analgesics within 6 months before vaccination or difficult to comply with the clinical trial procedure at the judgment of the investigator.
26. Administered to other investigational product or medical device within 6 months before vaccination.
27. Other vaccination history within 30 days prior to vaccination or being scheduled within 30 days after vaccination.
28. Receipt of immunoglobulin or any blood product within 3 month prior to vaccination.
29. Pregnant(including positive hCG test at screening visit) or breastfeeding female.
30. Current smoker or vaper. (use of cigarette or e-cigarette at least once in last 30 days, Part A only)
31. Those who are directly related to the investigator.
32. Other condition deemed ineligible for the study at the discretion of investigator.
19 Years
64 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cellid Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Ansan Hospital
Ansan, Province, South Korea
The Catholic University of Korea, ST. Vincent's Hospital
Suwon, Province, South Korea
Hallym University Kangnam Sacred Heart Hospital
Seoul, State, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, State, South Korea
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AdCLD-CoV19-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.